Company ProfilePremium

Algorae Pharmaceuticals Limited (formerly Living Cell Technologies Limited)

Company Profile Analysis

Ticker: 1AI.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Algorae Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

1987

48 Employees

Algorae Pharmaceuticals Limited logo

Algorae Pharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Algorae Pharmaceuticals Limited Overview

Algorae Pharmaceuticals is an Australian micro-cap that has spent the past four years turning a dormant xenotransplantation biotech, Living Cell Technologies, into a self-described "AI-enabled pharmaceutical company" with two tracks.

The discovery track is built around AlgoraeOS, a proprietary deep-learning platform developed with the UNSW AI Institute and supported by CSIRO Data61. AlgoraeOS predicts synergistic drug combinations. Its candidates are fixed-dose combinations: AI-116 (donepezil plus cannabidiol) for dementia and AI-168 (beta-blocker plus cannabidiol) for cardiovascular disease. The legacy NTCELL encapsulated-cell implant for Parkinson's disease remains under review.

The commercial track is AlgoraeRx, which is building a licensed generic and specialty medicines business in Australia and New Zealand. It has partners in India (Sakar, Cadila, Dr. Reddy's, Zydus and Torrent) and a NSW Health hospital supply contract.

The company had no product revenue in FY2026 and remains reliant on equity raisings. It is an early-stage, high-optionality, high-execution-risk story trading at roughly A$26m market capitalisation.


Company's own description (FY2026 Annual Report)

The FY2026 directors' report describes Algorae as an AI-enabled pharmaceutical company operating a synergistic dual-track business that combines AI-driven drug discovery with pharmaceutical commercialisation.

Discovery: is built around AlgoraeOS, its proprietary AI drug-combination prediction platform, together with a therapeutic pipeline comprising AI-116 for dementia and AI-168 for cardiovascular disease.

Commercial activities: are conducted through the wholly owned subsidiary AlgoraeRx Pty Ltd. AlgoraeRx sources, licenses, registers and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels.

Management characterised FY2026 as "a year of transition", in which the group moved from a single-track R&D business to a dual-track model. No product revenue was recognised during the year.

Independent characterisation

In substance, Algorae today is three things.

(a) A small AI/computational biology research programme.

  • It is largely outsourced to UNSW (Master Research Agreement, total fee A$726,565) and to the Peter MacCallum Cancer Centre's Victorian Centre for Functional Genomics (VCFG) for wet-lab validation.

  • Its output is ranked lists of predicted drug-pair synergies, which the company intends to convert into patentable fixed-dose combinations, often repurposing off-patent drugs.

  • This is a capital-light "asset generation" model. Value creation depends on securing patent positions on combinations and then licensing or developing them.

(b) A start-up generic pharmaceutical sponsor/distributor (AlgoraeRx).

  • It in-licenses dossiers or finished products from Indian manufacturers.

  • It acts as Australian TGA sponsor, manages registration, pricing and reimbursement, and sells to hospitals, pharmacies and institutional buyers.

  • It is a low-margin, volume-driven, regulatory-execution business that could provide recurring revenue far sooner than the discovery track.

  • The first stock was received in FY2026: inventory of A$180,744 and a first Dr. Reddy's capecitabine shipment in January 2026.

(c) A legacy cell-therapy shell.

  • This comprises NTCELL, Living Cell Technologies NZ, carried-forward tax losses of A$46.2m, and NZ R&D loss tax credits of A$1.78m that are contingently repayable.

Business and revenue model

DimensionCurrent state (FY2026)
Revenue model mix100% interest income (A$77,667). No product, service, subscription or licensing revenue recognised.
Expected near-term revenue sourceProduct sales by AlgoraeRx: generic oncology, cardiovascular, metabolic and specialty medicines. First NSW Health supply orders were expected in Q4 calendar 2026.
Longer-term revenue sourceOut-licensing or partnering of AI-derived combination drug candidates and IP; potential platform collaborations (n/d).
Value chain positionDiscovery: in-silico target and combination identification upstream of preclinical. Commercial: sponsor, regulatory holder and market-access layer between offshore manufacturers and ANZ wholesalers/hospitals.
Customer typesPublic hospitals (NSW Health standing offer), pharmacies, institutional buyers, wholesalers; future pharma licensees for discovery assets.
End-marketsANZ generic prescription medicines (oncology, cardiovascular, metabolic, injectables/specialty); dementia/Alzheimer's; cardiovascular disease; Parkinson's disease (legacy).
Geographic focusAustralia (predominant) and New Zealand

Strategy

Stated strategy (FY2026 AR, paraphrased tenets)

  1. Maintain a dynamic, innovative culture focused on emergent pharmaceutical development themes.

  2. Expand the R&D project pipeline to diversify value-generating activities.

  3. Build a diversified, multi-partner commercial portfolio of generic and specialty medicines and take products through TGA registration to market.

  4. Collaborate with industry, CROs and universities.

  5. Implement a robust IP strategy.

  6. Ensure adequate funding for research, development and commercial activities.

The stated objective is value creation through clinically validated IP plus a recurring commercial revenue base.

FY2027 stated priorities

  • Progress TGA registration submissions across the licensed portfolio.

  • Commence supply under commercial agreements, including the NSW Health contract (first orders expected Q4 CY2026).

  • Complete the second Peter Mac/VCFG validation of AOS2 (full dataset within ~6 months of the March 2026 start).

  • Finalise the shortlist from the multi-anchor AOS2 prediction set.

Initiative register (last 24 months)

DateInitiativeTypeDetail
Jun 2025Commercial build-outNew businessCCO hire; AlgoraeRx established
Sep 2025 – May 2026Five manufacturer agreementsPartnershipsSakar, Cadila, Dr. Reddy's, Zydus, Torrent
Nov 2025AOS2 launchPlatform investmentBenchmarked against DeepMind TxGemma
Nov–Dec 2025Loyalty Options OfferCapital1-for-5 options at A$0.001 (exercise A$0.014, expiry Dec 2029); A$199k plus A$139k shortfall
Jan 2026ScotPac A$3.0m facilityWorking capitalBBSY + 6.70%, 24 months, undrawn
Mar 2026Second Peter Mac programmeValidation24 combinations across 4 cancer lines
Apr 2026First TGA dossier acceptedRegulatoryA second dossier was accepted by the June quarter
May 2026Multi-anchor AOS2Pipeline18 anchors; >9m predictions
23–29 Jun 2026AgenticScale.ai SOW (A$120k) and Sovereign AI Infrastructure launch partnerAI infrastructureNVIDIA-based sovereign compute
Jul 2026NSW Health supply contractCommercial3+1+1 years

Cost programmes: none announced.

ESG commitments: none disclosed.

Medium-term financial targets: none formally guided. Implicit targets are embedded in performance-rights hurdles: A$10m, A$15m and A$25m revenue at ≥20% EBIT margin, and market capitalisation of A$75m–A$250m. These are incentive hurdles, not guidance.

Products & Services

No product has yet generated recognised revenue. Products are listed by track.

Discovery platform

OfferingDescriptionKey specifications / capabilitiesTarget userVersion / yearPricing
AlgoraeOS v1 (AOS1)AI drug-combination synergy prediction platformUsed to select 21 CBD-partner drugs (plus 3 investigational) for validation; 96 preclinical assessments across 4 cancer cell lines (T98G, BT20, PANC1, 22Rv1); ~10,000 data pointsInternal pipeline generationBuilt 2023–2025 with UNSWInternal; not sold
AlgoraeOS v2 (AOS2)Uncertainty-aware deep-learning upgradeSee detail belowInternal; potential partnersLaunched 10 Nov 2025Internal; n/d
AOS2 single-anchor programme (CBD)CBD × >3,000 approved/investigational drugs × 170 cell lines>500,000 combinations scored; 90 high-quality candidates; 24 selected for second Peter Mac validationInternalDec 2025—
AOS2 multi-anchor programmeExtension to 18 additional anchor drugs>9 million predictions; >478,000 passing initial thresholds; >6,000 combinations with multi-cell-line synergy; curation underwayInternal18 May 2026—

AOS2 key specifications:

  • Trained on >5.5m unique inhibition records (~11m with augmentation).

  • Models the full dose–response surface.

  • Predicts Bliss, Loewe, HSA and ZIP synergy measures simultaneously.

  • Produces aleatoric and epistemic uncertainty estimates.

  • On the NCI-ALMANAC benchmark, ZIP MAE 2.89 and Loewe MAE 6.46. The comparison models scored ZIP 3.78 / Loewe 17.38 (Tx-LLM (M)) and ZIP 3.81 / Loewe 17.34 (TxGemma-27B-Predict).

Therapeutic pipeline (preclinical unless noted)

CandidateComposition / modalityIndicationPartnerStageIP
AI-116Fixed-dose combination of donepezil plus cannabidiol (CBD)Dementia including Alzheimer's disease—Preclinical; no material new results announced in FY2026PCT application filed
AI-168Fixed-dose combination of a beta-blocker plus CBDCardiovascular disease (vascular cell dysfunction)Victorian Heart Institute, Monash UniversityPreclinical; no material new results in FY2026PCT application filed
NTCELLAlginate-coated capsule containing neonatal porcine choroid plexus cells (IMMUPEL immunoprotective coating)Parkinson's disease—Legacy; Phase IIb completed historically; under strategic review led by CSOLegacy encapsulation IP
LP-003Anti-obesity drug candidateObesity—Listed by Morningstar; not described in FY2026 AR—
LC-002Migraine treatment candidateMigraine—Listed by Morningstar; not described in FY2026 AR—
24 AI-generated oncology targets / combinationsAOS-derived combinationsOncology (glioblastoma, rhabdomyosarcoma, melanoma, CML cell models in second Peter Mac programme)Peter MacCallum Cancer Centre (VCFG)In-vitro validationWholly owned (per company)

Commercial portfolio — AlgoraeRx (ANZ generics and specialty)

PartnerAgreement dateScopeProducts namedStatus (FY2026 AR)
Sakar Healthcare Ltd (NSE: SAKAR)23 Sep 2025 (exclusive licence)5 generic oncology medicines, ANZn/d (aggregator cites initial ~A$10m annual addressable market)Licence fee commitment US$110k, of which US$25k paid
Cadila Pharmaceuticals LtdTerm sheet 20 Oct 2025; definitive Licence & Supply Agreement 9 Feb 20262 generics, cardiovascular/metabolic—TGA registration planning commenced; licence fee commitment A$45k
Dr. Reddy's Laboratories (NSE: DRREDDY; NYSE: RDY)27 Nov 2025 (distribution)Supply into AustraliaCapecitabine 500 mg tablets (chemotherapy)First shipment January 2026
Zydus Lifesciences (NSE: ZYDUSLIFE)28 Apr 2026 (exclusive commercial and licensing)10 injectable, oral and specialty products, ANZ—Joint prioritisation; subject to TGA approvals
Torrent Pharmaceuticals (NSE: TORNTPHARM)6 May 2026 (Licence & Supply)2 generic prescription molecules, phased—Phase 1 uses existing or cloned registrations; Phase 2 requires new TGA registrations
NSW Health (customer)1 Jul 2026 (standing offer)Supply of one awarded product to NSW public hospitalsConfidentialNo minimum volumes; first orders expected Q4 CY2026

Pricing for all commercial products is n/d (commercial-in-confidence).

Financial Detail

Group Entities

EntityCountryOwnershipRole

Algorae Pharmaceuticals Limited

Australia

Parent

Listed holding company; head office

AlgoraeRx Pty Ltd

Australia

100%

Commercial pharmaceuticals (TGA sponsor, sales, distribution)

Algorae Sciences Pty Ltd

Australia

100% (new in FY2026)

Science/R&D vehicle (purpose not separately described)

Living Cell Products Pty Ltd

Australia

100%

Legacy cell-therapy entity

Living Cell Technologies New Zealand Ltd

New Zealand

100%

Legacy NTCELL R&D entity; NZ R&D tax credits

Revenue by Segment (AUD)

Segment metric (AUD)FY2025FY2026

R&D – operating expenses

-825,167-1,005,549

R&D – R&D tax credits

737,178384,467

R&D – segment result

-72,418-621,082

Distribution – operating expenses

-59,366-697,086

Distribution – segment result

-59,366-751,704

Head Office – interest income

141,05077,667

Head Office – segment result

-794,235-1,509,390

Eliminations

123,061171,453

Consolidated result

-802,958-2,710,723

Segment revenue (AUD)

Segment revenue (AUD)FY2024FY2025FY2026

Research and Development

000

Distribution (AlgoraeRx)

000

Head Office (interest/other income)

125,200141,05077,667

Segment Overview

SegmentTotal assets (AUD)Total liabilities (AUD)

Research and Development

17,760

33,472,517 (intercompany)

Distribution

409,854

1,193,922 (mostly intercompany)

Head Office

5,145,24487,229

Eliminations

(1,134,803)(34,576,946)

Consolidated

4,438,055176,721

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue and other income (AUD K)

3.442.0125.2141.177.7

Of which product/service revenue (AUD K)

00000

Gross profit (AUD K)

00000

Total expenses (AUD K)

———1,696.53,168.3

Operating loss (AUD K)

———-1,555.5-3,090.6

EBITDA (AUD K, ≈ operating loss; no D&A disclosed)

———-1,555.5-3,090.6

Loss before tax (AUD K)

——-2,095.6-1,540.1-3,095.2

Income tax benefit, R&D refund (AUD K)

——0737.2384.5

Net loss (AUD K)

-1,957.3-2,107.7-2,095.6-803.0-2,710.7

Basic and diluted EPS (A$ cents)

-0.22-0.16-0.13-0.05-0.15

Dividends per share (A$ cents)

00000

Share price at FYE (AUD)

0.0080.0150.0100.0050.010

Expense line (AUD K)

Expense line (AUD K)FY2025FY2026

Research and development

854.6940.8

Distribution (AlgoraeRx)

0633.2

Share-based payments

35.7490.0

Governance (director fees, consultancy, other)

626.8848.1

Administrative

176.3229.1

Borrowing expense

3.027.0

Total expenses

1,696.53,168.3

Balance Sheet

Metric (AUD K)FY2024FY2025FY2026

Cash at bank

808.4469.23,187.3

Term deposits

2,300.01,850.0750.0

Total cash and deposits

3,108.42,319.23,937.3

Inventories

00180.7

Total assets

3,1902,398.64,438.1

Total liabilities

176169.8176.7

Total debt

000

Net debt (negative = net cash)

-3,108.4-2,319.2-3,937.3

Total equity

3,014.32,228.84,261.3

Goodwill and intangibles

000

Working capital

3,0142,228.84,261.3

Issued capital

—81,540.885,473.4

Accumulated losses

-79,083.6-79,885.3-82,057.6

Cash Flow

Metric (AUD K)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

-2,042.2-1,986.3-1,523.3-785.3-2,603.9

Capex

00000

Free cash flow

-2,042.2-1,986.3-1,523.3-785.3-2,603.9

Net investing cash flow, term deposits (AUD K)

———450.01,100.0

Net financing cash flow (AUD K)

———-3.04,225.0

Equity raised, gross, incl. option exercises (AUD K)

———04,381.5

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Returns & Leverage Ratios (%)

RatioFY2025FY2026

ROE (%, on average equity)

-30.6-83.5

ROA (%, on average assets)

-28.7-79.3

ROIC (%)

ROIC (%)n/mn/m

Current ratio (x)

14.125.1

Debt / equity (x)

00

Net debt / EBITDA (x)

Net debt / EBITDA (x)n/mn/m

Interest coverage (x)

n/m

n/m

Asset turnover (x)

00

Cash conversion cycle (days)

n/m

n/m

Region revenue (AUD K)

Region revenue (AUD K)FY2024FY2025FY2026

Australia (interest/other income)

125.2141.177.7

New Zealand

000

Rest of world

000

Share Price and Share Count (m)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at FYE (AUD)

0.0080.0150.0100.0050.010

Shares on issue at FYE (m)

——1,687.41,687.42,025.6

Market cap at FYE (AUD Mn)

——16.98.420.3

Performance Details

Performance (to 30 Jun 2026, FYE-based)Return

1-year

+100% (A$0.005 to A$0.010)

3-year

-33% (A$0.015 to A$0.010)

5-year

-17% (A$0.012 on 30 Jun 2021 to A$0.010)

Long-run

-91% versus A$0.11 at 30 Jun 2017

Last verified trade

A$0.013 (24 Jul 2026)

Valuation Multiples

MultipleAlgoraeComment

Market cap

~A$26.4m

—

Enterprise value

~A$22.4m

Market cap less A$3.94m cash and deposits

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

No sales

P/B

~6.2x

Book equity A$4.26m

P/NTA

~5.4x

NTA 0.24c per share

Capital Markets

ItemStatus

Analyst consensus

None. No major broker coverage (Market Index).

Dividend history and policy

No dividends ever paid; none expected

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No debt. The A$3.0m ScotPac facility (24-month term from 20 Jan 2026, expiring ~Jan 2028) is undrawn.

Outstanding equity instruments

376,423,855 unlisted options (A$0.014, expiry 1 Dec 2029); 179m performance rights at 30 Jun 2026 (35m lapsed July 2026; 2m converted)

Liquidity

Highly variable (e.g. 9.7k to 1.8m shares per day in July 2026)

ASX ranking

~1,598 of 2,336 ASX companies by market cap (Market Index, when still shown as LCT)

Analyst Conclusions

Management guidance

No financial guidance has been given. Operational priorities for FY2027 are:

  • TGA submissions across the licensed portfolio.

  • Commencement of supply under commercial agreements, including NSW Health from Q4 CY2026.

  • Completion of the second Peter Mac validation.

  • A shortlist from the multi-anchor AOS2 set.

There are no consensus estimates.

Bull case

  1. First revenue imminent. NSW Health orders from Q4 CY2026, capecitabine stock already received and two TGA dossiers in evaluation could deliver Algorae's first product revenue in FY2027. That would allow ScotPac drawdowns and reduce reliance on equity.

  2. Option value on the platform. Two independent Peter Mac validations, AOS2 benchmark outperformance and a pool of >6,000 multi-cell-line synergistic combinations offer cheap optionality. An EV of ~A$22m ascribes little value to the platform.

  3. Funding pathway in place. Debt-free balance sheet, A$3.9m liquidity, an undrawn A$3m facility and ~A$5.3m of in-the-money-on-recovery options provide a credible bridge. Management incentives are tied to A$10m–A$25m revenue at ≥20% EBIT margin.

Bear case

  1. Dilutive pre-revenue spending. Zero product revenue, burn rising to ~A$2.6m+ per year, and governance/admin costs above R&D suggest another raise within 12–18 months at about one cent per share. Shares outstanding already rose 20% in FY2026.

  2. Commercial economics unproven. The NSW contract has no volume commitment, ANZ generic margins are thin, and incumbents dominate tenders. Revenue scale relative to the A$10m incentive hurdles is speculative.

  3. Pipeline and governance concerns. AI-116 and AI-168 produced no new data in FY2026, NTCELL is dormant, platform claims are not yet peer-reviewed, and governance is concentrated in a three-person board with shared adviser ties and no committees.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct 2026Q1 FY2027 4C: cash balance, burn, first receipts
5 Nov 2026AGM: auditor ratification, new incentives, placement capacity
Q4 CY2026First NSW Health supply orders; first product revenue recognition
H2 CY2026 – H1 CY2027Outcome of TGA evaluation of first two dossiers; further dossier lodgements (Cadila, Zydus, Torrent Phase 1)
~Sep 2026 – Q1 CY2027Full dataset from second Peter Mac validation (AOS2, 24 combinations)
H1 CY2027Multi-anchor AOS2 shortlist; new patent filings; peer-reviewed publication
OngoingCapital raising terms; ScotPac drawdown; NTCELL strategic decision; board renewal and independence
27 Feb 2027 (expected)H1 FY2027 results

Analyst verdict

Algorae Pharmaceuticals is best understood as a recapitalised shell in the middle of a deliberate reinvention, rather than as a continuation of Living Cell Technologies' decades-long xenotransplantation programme. That legacy consumed roughly A$80m of shareholder capital and left behind tax losses, a dormant Parkinson's implant and a listing.

Since October 2022, a capital-markets-led board has rebuilt the company around two ideas: a low-cost AI combination-synergy platform and a pragmatic ANZ generics sponsor business. FY2026 was the year the second idea became tangible. Five Indian manufacturing partners were signed, a Sandoz- and EBOS-trained commercial team was assembled, two TGA dossiers were accepted, stock was received and a NSW Health supply appointment was won.

The difficulty is that none of this has yet produced a dollar of product revenue. Cash burn tripled to A$2.6m, share-based payments rose sharply and corporate overhead now exceeds R&D spend. The discovery track has produced encouraging but early in-vitro validation and impressive-sounding benchmark numbers. However, the named clinical candidates showed no material progress during the year, and the platform's commercial model (licensing, partnering or internal development) remains undefined.

At roughly A$26m market capitalisation and about A$22m enterprise value, the market is pricing a modest probability that AlgoraeRx becomes a real revenue business, with little value assigned to the AI pipeline. That is not unreasonable. The investment case over the next 12 months is binary on commercial execution. Conversion of NSW Health and TGA milestones into recurring, receivable-backed revenue would de-risk funding, validate management's revenue-linked incentives and give the AI track time to mature. Failure would likely mean further deep-discount dilution.

Assessment: speculative, high-risk, execution-dependent. Monitor quarterly cash flows and first revenue recognition closely. Governance improvements, specifically independent directors and audit and remuneration committees, would materially improve the risk profile.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundQualificationsIndependence

David Hainsworth

Executive Chairman (also functions as CEO)

31 Oct 2022

25+ years in capital markets; investment adviser at Euroz Hartleys; Alignment Capital Pty Ltd

BSc

Not independent (executive)

David Gulland

Non-executive director; also COO of AlgoraeRx (from 23 Mar 2026)

10 Mar 2026

Former General Manager, HPS Pharmacies (EBOS Group); 20+ years in hospital pharmacy/medicines supply

MPharm, BSc

Classified non-independent by the board

Troy Valentine

Non-executive director

14 Jul 2026

Chairman, Incannex Healthcare Inc. (Nasdaq: IXHL) since Nov 2023; co-founder of Alignment Capital; ex-Patersons/Canaccord, Hartley Poynton

BCom

Independence n/d; Alignment Capital link suggests limited independence

Executive Leadership Team

NameRoleSinceBackground

Vishal Shah

Managing Director, AlgoraeRx (initially Chief Commercial Officer)

30 Jun 2025

n/d in AR beyond role

David Gulland

COO, AlgoraeRx

23 Mar 2026

See board table

Waleed Elsayed

Head of Sales

Appointed Mar 2026; commenced Q2 2026

Former Head of Hospital Sales, Sandoz ANZ

Dr James McKenna

Chief Scientific Officer

—

Co-supervised Peter Mac validation; leads NTCELL review

Geraldine Holland and Catherine Earlie

Joint Company Secretaries

1 Jul 2026

Replaced Jennifer Voon (stepped down 30 Jun 2026)

Prof Carolyn Sue

Former CMO (NTCELL) / Medical Advisory Board

~2019

Options forfeited FY2025; current role n/d

Directors' Remuneration

PersonCash salary/feesBonusSuperannuationShare-basedTotal FY2026Total FY2025

David Hainsworth

232,500026,40029,182288,082126,879

Bradley Dilkes

50,0000020,53070,53087,269

Bradley Latham

34,5430076,012110,55569,522

David Gulland

70,89006,6459,01286,547—

Vishal Shah

214,586024,00027,000265,58656,857

Total KMP

602,519

0

57,045

161,736

821,300

340,527

Major Shareholders

HolderShares% (approx.)Source

Chunyan Niu

93,251,315

5.53% (at notice; ~4.6% on 30 Jun 2026 share count)

Market Index substantial holder notice 26 Aug 2025

Bradley Dilkes and related entities (Cipater, Cichli)

52,150,000

~2.6%

FY2026 AR

David Hainsworth / Union Square Capital

25,937,500

~1.3%

FY2026 AR

Bradley Latham

20,000,000

~1.0%

FY2026 AR

David Gulland / Gull Health

3,279,333

~0.2%

FY2026 AR

Vishal Shah / Shah Global

3,166,667

~0.2%

FY2026 AR

Competitive Landscape

Key Competitors

CompetitorListingPositioning versus Algorae

Recursion Pharmaceuticals (merged with Exscientia, 2024)

Nasdaq: RXRX

Scaled phenomics plus AI platform with clinical pipeline; orders of magnitude larger

Insilico Medicine

Private (Hong Kong IPO activity reported; verify)

End-to-end generative AI; clinical-stage assets

Schrödinger

Nasdaq: SDGR

Physics-based computational platform with software revenue

Isomorphic Labs (Alphabet)

Private

Deep-learning structure and drug design; DeepMind's TxGemma was the AOS2 benchmark comparator

BenevolentAI

Status changed in 2025 (verify)

Knowledge-graph target discovery

Relay Therapeutics

Nasdaq: RLAY

Computational/structural precision medicine

Combination-specific academic tools (e.g. DeepSynergy-type models)

Academic

Open models in the same synergy-prediction niche

Incannex Healthcare

Nasdaq: IXHL

Cannabinoid fixed-dose combinations; shares chair and adviser network

Alterity Therapeutics

ASX: ATH

Neurodegeneration (MSA); clinical-stage

Zelira Therapeutics, Bod Science and other ASX cannabinoid-pharma names

ASX

CBD-based therapeutics

Key Competitors — Sandoz ANZ

CompetitorPositioning

Sandoz ANZ

Leading hospital generics/biosimilars; the new Head of Sales came from Sandoz

Viatris

Broad generics portfolio

Arrotex Pharmaceuticals

Largest Australian-owned generics company

Apotex Australia

Major generics supplier

Juno Pharmaceuticals

Specialty and hospital injectables

Dr. Reddy's, Sun Pharma, Cipla and other direct ANZ operations

Indian majors with own ANZ subsidiaries

EBOS Group (HPS)

Distributor/pharmacy services; the COO came from here

Peer Comparison FY2026

MetricAlgorae (FY2026)Top AI-discovery peerTop ANZ generic peerCannabinoid peer

Revenue (AUD Mn)

0.0

n/v

n/v

n/v

Revenue growth

n/m

n/v

n/v

n/v

Margins

n/m

n/v

n/v

n/v

R&D intensity

n/m (A$0.94m absolute)

n/v

n/v

n/v

Recent Developments

The 2 July 2026 share-price reaction is per the InvestSMART price display (A$0.013 to A$0.010) and should be treated as indicative.

Company Snapshot

48

Employees

1987

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean balance sheet. Zero debt, A$3.94m cash and deposits, total liabilities only A$176.7k (FY2026 AR).
  • Tier-1 partners. Five executed manufacturer agreements in eight months, including Dr. Reddy's, Zydus and Torrent (FY2026 AR).
  • Hospital channel access. NSW Health standing-offer appointment won via competitive tender, 3+1+1 years (1 Jul 2026).
  • Regulatory traction. Two TGA registration dossiers accepted for evaluation by June quarter 2026 (Q4 FY2026 4C).
  • External platform evidence. Independent validation at Peter Mac for AOS1 (Dec 2025) and improved predictive power in AOS2 (Jul 2026).
  • Benchmark performance. AOS2 reports a Loewe MAE of 6.46 against ~17.3 for DeepMind TxGemma-27B-Predict on NCI-ALMANAC (FY2026 AR).
  • Tax shield. A$46.2m of unused tax losses (FY2026 AR Note 4).
  • Experienced commercial hires. EBOS/HPS (Gulland) and Sandoz (Elsayed) backgrounds.

Weaknesses

  • No revenue. Zero product revenue in any of the last five years; income was solely A$77.7k of interest in FY2026.
  • Persistent losses. Five consecutive annual losses of A$0.8m–A$2.7m; accumulated losses of A$82.1m.
  • Overhead exceeds R&D. Governance plus admin costs of A$1.08m exceeded R&D of A$0.94m in FY2026.
  • Weak governance structures. No audit or remuneration committees; only 2–3 board meetings in FY2026; combined chair/CEO.
  • Board concentration. Hainsworth, Valentine and ex-director Dilkes all share Alignment Capital ties.
  • Stalled pipeline. No material new preclinical data for AI-116 or AI-168 in FY2026; NTCELL dormant under review.
  • Heavy dilution. Share count rose 20% in FY2026 (1,687m to 2,026m), with a further 376m options and ~140m+ rights outstanding.

Opportunities

  • NSW Health supply. First orders expected Q4 CY2026 could produce the company's first product revenue.
  • Large licensed portfolio. Up to ~21 licensed products (5 Sakar + 2 Cadila + 10 Zydus + 2 Torrent + capecitabine + NSW product) for staged ANZ launches.
  • Large candidate pool. The multi-anchor AOS2 set (>6,000 multi-cell-line synergistic combinations) provides out-licensing and IP candidates.
  • Working-capital funding. The A$3.0m ScotPac facility can fund inventory once receivables exist.
  • Option-exercise funding. 376.4m A$0.014 options could raise ~A$5.3m if the share price rises above A$0.014.
  • AI infrastructure partnering. The Sovereign AI Infrastructure launch-partner role could bring partnering or grant leverage.

Threats

  • Regulatory delay. TGA evaluation outcomes and timing are uncertain; the company explicitly cautions that acceptance does not indicate outcome.
  • No volume commitment. The NSW Health arrangement has no minimum volumes, so the financial impact is unquantifiable (2 Jul 2026).
  • Generic price erosion. Incumbents (Sandoz, Viatris, Arrotex) may compete aggressively on tender pricing.
  • Platform obsolescence. Well-funded AI-discovery competitors (Recursion, Isomorphic) could commoditise synergy prediction.
  • Further dilution. Funding needs are likely within 12–18 months at a share price of about one cent.
  • Contingent NZ clawback. A$1.78m of NZ R&D loss tax credits could be repaid on a >90% shareholding change or an IP sale, which constrains NTCELL disposal options (FY2026 AR Note 22).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Jun 2025Vishal Shah appointed Chief Commercial OfficerStart of commercial pivot
28 Jul 2025Performance rights granted to Shah (42m)Revenue/EBIT-linked incentives
26 Aug 2025Chunyan Niu substantial holding notice (5.53%)Largest disclosed holder
28 Aug 2025FY2025 results: net loss A$0.80m (down 62%); revenue and other income A$141kTrough loss aided by R&D refund
23 Sep 2025Exclusive licence with Sakar Healthcare (5 oncology generics)First commercial transaction
2 Oct 2025AGM: all resolutions passed; new Constitution; 10% placement capacityGovernance and capital flexibility
2 Oct 202560m director performance rights grantedMarket-cap/revenue hurdles
20 Oct 2025Binding term sheet with Cadila (2 CV/metabolic generics)Portfolio expansion
27 Oct 2025Lead manager mandate; 30m options and 100m performance rightsFunding infrastructure
28 Oct 2025Q1 FY2026 quarterly: operating outflow ~A$395k; cash A$1.92mLiquidity tightening pre-raise
10 Nov 2025AlgoraeOS v2 launched; benchmarks versus TxGemma/Tx-LLMPlatform credibility
17 Nov 2025Loyalty Options Offer announcedRetail-friendly capital
27 Nov 2025Dr. Reddy's distribution agreement (capecitabine 500 mg)First in-market product
5 Dec 2025AOS1 independent validation results (Peter Mac)First external evidence for platform
10 Dec 2025A$384,467 RDTI refund receivedNon-dilutive cash
12 Dec 2025AOS2 CBD single-anchor prediction set (>500k combinations; 90 candidates)Pipeline generation
Jan 2026First capecitabine shipment receivedFirst inventory
20–21 Jan 2026A$3.0m ScotPac receivables facilityWorking-capital readiness
9 Feb 2026Cadila definitive Licence & Supply AgreementConverted term sheet
10 Mar 2026Gulland joins board; Latham retiresBoard reshaped toward commerce
13 Mar 2026138.7m loyalty shortfall options issuedCapital
Mar 2026Waleed Elsayed (ex-Sandoz) appointed Head of Sales; team visits Ahmedabad partnersSales capability
30 Mar 2026Second Peter Mac validation agreement (AOS2; 24 combinations)Platform de-risking
31 Mar 20261AIO listed options (A$0.012) expireBulk exercised beforehand
2 Apr 2026A$3.99m raised; TGA accepts first registration dossierBalance-sheet repair; regulatory milestone
28 Apr 2026Zydus exclusive agreement (10 products)Largest portfolio deal
6 May 2026Torrent Licence & Supply AgreementFifth partner
18 May 2026Multi-anchor AOS2 results (>9m predictions; >478k passing filters)Pipeline scale
24 Jun 2026PKF Perth appointed auditor (PKF Brisbane resigned)Independence-driven change
29 Jun 2026Named launch partner of Sovereign AI Infrastructure (AgenticScale.ai / NVIDIA)AI infrastructure positioning
1–2 Jul 2026NSW Health supply contract plus supplementary clarification (no minimum volumes)First institutional contract; share price fell ~23% intraday on 2 Jul after clarification
3 Jul 2026AOS2 validation results: improved predictive power versus AOS1Platform progress
14 Jul 2026Troy Valentine joins board; Dilkes resignsAlignment Capital continuity
21 Jul 2026Cessation of 35m performance rightsFollows Dilkes' resignation
31 Jul 2026June-quarter 4C: five agreements; two TGA dossiers accepted; new Head of SalesExecution update
31 Aug 2026FY2026 annual report: net loss A$2.71m; net assets A$4.26m; unmodified audit opinionYear-end position
Scheduled 5 Nov 2026AGM (director nominations closed 16 Sep 2026)Upcoming

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (AUD): Totals: Eliminations rose from AUD 123,061 in FY2025 to AUD 171,453 in FY2026.
Algorae Pharmaceuticals Limited — Revenue by Segment (AUD): Totals
Series (AUD)FY2025FY2026
Eliminations123,061171,453
Consolidated result-802,958-2,710,723

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Algorae Pharmaceuticals Limited, Annual Report and Appendix 4E, year ended 30 June 2026 (released 31 August 2026), via investorpa.com / Webull announcement mirrors
  2. Algorae Pharmaceuticals Limited, Appendix 4E and Annual Report, year ended 30 June 2025 (28 August 2025), ASX announcements platform
  3. Algorae Pharmaceuticals Limited, Half Yearly Report ended 31 December 2025 (27 February 2026), ASX
  4. ASX announcements: Torrent LSA (6 May 2026); Capital raising (2 April 2026); NSW Health supplementary announcement (2 July 2026)
  5. InvestSMART price-sensitive announcement summaries: Q1 FY2026 quarterly (28 Oct 2025); multi-anchor AOS2 (18 May 2026); NSW Health (2 Jul 2026); AOS2 validation (3 Jul 2026)
  6. InvestorPA summary: Quarterly Activities Report / Appendix 4C, quarter ended 30 June 2026 (31 Jul 2026)
  7. Market Index (marketindex.com.au): 1AI and LCT pages (director holdings, substantial holders, FYE prices)
  8. Stocklight: LCT renamed to 1AI on 12 Sep 2023; annual report archive
  9. Stockhead company page (name change; historical NTCELL coverage headlines)
  10. SmallCaps.com.au: "ASX biotech company LCT eyes AI-powered drug discovery" (2023)
  11. LabOnline: "Long journey, but Living Cell Technologies finally nears market" (20 April 2004)
  12. Stoxray (historical revenue, net income and operating cash flow series; aggregator)
  13. financialfilings.com (FY2024 summary financials; filing list)
  14. ROIC.ai (OTC: LVCLF profile and 2025 commercial developments)
  15. Morningstar Australia (company profile; employees figure flagged unreliable)
  16. Investing.com (officer ages; listing symbols)
  17. EODData (ISIN, FIGI, July 2026 prices)
  18. TipRanks announcement summaries (AGM results; AOS2 launch)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.